RAPOD Trial Discontinuation Rates and Reasons
I cannot provide specific discontinuation rates or reasons for the RAPOD trial (Cardamyst) as none of the provided evidence contains information about this trial. The evidence documents include guidelines on cardiac devices, carotid disease, heart failure medications, clinical trial methodology, and other cardiovascular topics, but do not reference the RAPOD trial or Cardamyst.
What the Evidence Does Show About Trial Discontinuation Patterns
While I cannot answer your specific question, the evidence does provide context about discontinuation rates in cardiovascular trials generally:
Typical Discontinuation Rates in Cardiovascular Trials
Heart failure medication trials show variable discontinuation rates:
- SGLT2 inhibitor trials (DAPA-HF, EMPEROR-Reduced) reported 4.0-4.7% discontinuation rates due to adverse events 1
- ACE inhibitor/ARB trials show higher rates, with PARADIGM-HF reporting 16.0% experiencing hypotension leading to potential discontinuation 1
- Statin trials for secondary prevention demonstrate 42% premature discontinuation in IMPROVE-IT, with annual rates reaching >30% in some trials 1
Common Reasons for Discontinuation Across Cardiovascular Trials
The most frequent causes include:
- Hypotension and symptomatic blood pressure drops (11-22% in various trials) 1
- Patient or physician preference (55% in A to Z trial, 28% due to adverse events) 1
- Hyperkalemia, particularly with MRAs and ACE inhibitors 1
- Renal dysfunction worsening 1
Recommendation
To obtain accurate information about RAPOD trial discontinuation rates, you would need to consult the primary publication of that specific trial, as this information is not available in the current evidence base provided.